Lv4
698 积分 2024-10-14 加入
Novel Constructs—Half-Life Extensions
6天前
已完结
A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients with Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy
8天前
已关闭
Novel Constructs—Half-Life Extensions
8天前
已完结
5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer - NCT06179069
11天前
已完结
A DLL3-targeted theranostic for small cell lung cancer: Imaging a low density target with a site-specifically modified radioimmunoconjugate
14天前
已关闭
ImmunoPET in high-grade neuroendocrine tumours
15天前
已完结
MC339, a novel radiopharmaceutical, targets DLL3-expressing cancers of different tissue origins
15天前
已完结
Imaging with [89Zr] Zr-DFO-SC16. 56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
20天前
已关闭
Therapeutic efficacy and dosimetry for a 177-lutetium radiolabeled minibody targeting DLL3 in a preclinical model of small cell lung cancer
20天前
已关闭
皖公网安备34019202002308
